SNPジェノタイピングの世界市場 - 成長、動向、予測（2022年～2027年）

世界のSNPジェノタイピング市場は2018年に123億米ドルとなりました。今後は 21％のCAGRで拡大し、2024年には386億米ドルに達すると予測されています。

当レポートでは、世界のSNPジェノタイピング市場を調査し、市場の概要、タイプ、地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

• 調査成果
• 調査の前提条件
• 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

• 市場概況
• 成長要因
• 阻害要因
• ファイブフォース分析
  • 新規参入の脅威
  • 買い手の交渉力
  • サプライヤーの交渉力
  • 代替製品およびサービスの脅威
  • 業界内での競争

第5章 市場セグメンテーション

• 技術別
  • TaqMan SNPジェノタイピング
  • Massarray SNPジェノタイピング
  • SNP GeneChipアレイ
  • その他
• エンドユーザー別
  • 薬理ゲノミクス
  • 診断領域
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 中東＆アフリカ
  • 南米

第6章 競合情勢

• 企業プロファイル
  • Agilent Technologies Inc.
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • Douglas Scientific LLC
  • Illumina Inc.
  • Life Technologies Corp.
  • Luminex Corp.
  • Promega Corporation
  • Thermo Fischer Scientific Inc.

第7章 市場機会および将来動向

The global SNP genotyping market is expected to register a CAGR of 21% druing the forecast period. The analysis of SNPs is widely utilized in different disciplines of genetics and related studies, commonly associated with studying genetic determinants of many complex diseases. SNP technologies are extensively utilized for detection and are beneficial in the etiology of several human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, among others.

In addition, SNPs are essential markers in various human ailments and are intensely employed in pharmacogenomics to customize personalized medicine in a better way. Therefore, rising applications of SNPs in several life sciences and biotechnology aspects are driving the SNP genotyping market.

Key Market Trends

Pharmacogenomics Led the End-user Segment of the SNP Genotyping Market

Under end users, pharmacogenomics is the leading segment. The large share of pharmacogenomics is primarily due to the increasing pipeline for personalized medicine and novel drug delivery systems, which are extensively exploiting SNP in genetic materials for drug development applications. According to the Journal of Personalized Medicine, upto June 2019, there were around 132 pharmacogenimic guidlines for the available drugs and also, pharmacogenomic information is added in around 309 medication label. Hence, the growing demand for pharmacogenomics is expected to propel the SNP Genotyping market in this segment.

North America had Largest Share in the Global SNP Market, while Asia-Pacific is the Fastest-growing Region

North America is the dominating region in the SNP genotyping market, due to rising commercial research in personalized medicines and animal breeding, among others.In addition, Asia-Pacific is the fastest-growing market, due to the rising demand for SNP genotyping in emerging economies like China and India, across different fields, which is largely propelling the market's growth.

Competitive Landscape

The SNP genotyping market is highly competitive and consists of several major players. In terms of market share, a small number of the major players currently dominate the market. Key strategies adopted by major players in this market include product launches, collaborations, and agreements.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Miniaturisation of Equipment and Instruments
  • 4.2.2 Increased Multiplexing Capacity Leading to Increased Application
• 4.3 Market Restraints
  • 4.3.1 Lack of Standardisation in SNP Processes
  • 4.3.2 Privacy Concerns Pose a Threat to Broad Technology Adoption
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products and Services
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 Technology
  • 5.1.1 TaqMan SNP Genotyping
  • 5.1.2 Massarray SNP Genotyping
  • 5.1.3 SNP GeneChip Arrays
  • 5.1.4 Other Technologies
• 5.2 End User
  • 5.2.1 Pharmacogenomics
  • 5.2.2 Diagnostic Field
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle-East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East & Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Agilent Technologies Inc.
  • 6.1.2 Bio-Rad Laboratories Inc.
  • 6.1.3 Danaher Corporation
  • 6.1.4 Douglas Scientific LLC
  • 6.1.5 Illumina Inc.
  • 6.1.6 Life Technologies Corp.
  • 6.1.7 Luminex Corp.
  • 6.1.8 Promega Corporation
  • 6.1.9 Thermo Fischer Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS